Continuing Education Information
© 2017 Harborside™
ARTICLE
Understanding the Role of Targets and Pathways in the Treatment of Chronic Lymphocytic Leukemia
A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
Release date: 12/19/2017
Expiration date: 12/18/2018
Estimated time to complete activity: 3.0 hours
| Annenberg Center for Health Sciences at Eisenhower 39000 Bob Hope Drive, Dinah Shore Bldg. Rancho Mirage, CA 92270 Voice: 760-773-4500 Fax: 760-773-4513 E-mail: contactce@annenberg.net |
Journal of the Advanced Practitioner in Oncology |
© 2017, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.
This activity is supported by unrestricted educational grants from Gilead Sciences Inc. and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Faculty
Christopher Arp, PharmD, Levine Cancer Institute—Carolinas HealthCare System, Department of Pharmacy
Kristan Augustin, PharmD, BCOP, Barnes-Jewish Hospital, Department of Pharmacy
Hani M. Babiker, MD, University of Arizona College of Medicine, Translational Genomics Research Institute, and University of Arizona Cancer Center
Andrew Garcia, PharmD, The University of Arizona Cancer Center
Ashley E. Glode, PharmD, BCOP, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Amy Goodrich, MSN, CRNP, Johns Hopkins School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Alyssa Hinchman, PharmD, The University of Arizona Cancer Center
Lindsay Hladnik, PharmD, BCOP, Washington University in Saint Louis School of Medicine, Department of Medicine
Nadia Khan, MD, Fox Chase Cancer Center
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, The University of Arizona Cancer Center
Ali McBride, PharmD, BCOP, The University of Arizona Cancer Center
Lisa Nodzon, PhD, ARNP, AOCNP®, Department of Malignant Hematology, Moffitt Cancer Center
Javier Pinilla-Ibarz, MD, PhD, Department of Malignant Hematology, Moffitt Cancer Center
Barbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, Fox Chase Cancer Center
Nina Wagner-Johnston, MD, Johns Hopkins School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Activity Rationale and Purpose
Chronic lymphocytic leukemia (CLL), characterized by uncontrolled proliferation of malignant B lymphocytes, is the most common leukemia in Western countries. With a population primarily over 70 years of age, frailty and comorbidities are common concerns with established chemoimmunotherapy. Since 2014, new therapies have been approved by the FDA, leading to specialized, specific treatments for the different stages of CLL. This education will review these novel therapies and describe the need for proper diagnostic procedures prior to treatment initiation and monitoring.
Intended Audience
The activity’s target audience will consist of nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
Learning Objectives
After completing this educational activity, participants should be able to:
- Discuss the prominent pathways and targets for novel agents used to treat CLL, including monoclonal antibodies, immunotherapies, small-molecule inhibitors, and immunomodulatory agents.
- Apply updated clinical practice guidelines on dosing and response monitoring.
- Apply strategies for the prevention and management of adverse events associated with novel therapies used in the treatment of patients with CLL.
Continuing Education
Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.
Physicians. The Annenberg Center for Health Sciences at Eisenhower has been awarded Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME®).
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses. The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider
of continuing nursing education by the American Nurses Credentialing Center’s Commission
on Accreditation.
A maximum of 3.0 contact hours may be earned for successful completion of this activity.
Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 3.0 contact hours.
Pharmacists. This knowledge-based accredited educational activity is intended for pharmacists involved in the care of cancer patients. This educational activity is provided by the Annenberg Center for Health Sciences at Eisenhower.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is assigned ACPE Universal Program #0797-9999-17-122-H01-P. This program is designated for up to 3.0 contact hours (0.3 CEU) of continuing pharmacy education credit.
Financial Disclosures
All individuals in positions to control the content of this program (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the ACHS policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Disclosures
Faculty
Christopher Arp, PharmD, has nothing to disclose.
Kristan Augustin, PharmD, BCOP, has nothing to disclose.
Hani M. Babiker, MD, has nothing to disclose.
Andrew Garcia, PharmD, has nothing to disclose.
Ashley E. Glode, PharmD, BCOP, has nothing to disclose.
Amy Goodrich, MSN, CRNP, has served on the speakers bureau for Gilead.
Alyssa Hinchman, PharmD, has nothing to disclose.
Lindsay Hladnik, PharmD, BCOP, has nothing to disclose.
Nadia Khan, MD, has served as a consultant for AbbVie and has served on the speakers bureau for Genentech.
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, has served as a consultant for AbbVie, Celgene, Genentech, and Pharmacyclics.
Ali McBride, PharmD, BCOP, has served on speakers bureaus for AbbVie and Incyte.
Lisa Nodzon, PhD, ARNP, AOCNP®, has served as a consultant for Ariad and Gilead; has served on speakers bureaus for Ariad, Bristol-Myers Squibb, Genentech, Gilead, Novartis, and Pfizer; and has received payment for the development of educational presentations for Genentech/AbbVie.
Javier Pinilla-Ibarz, MD, PhD, has received consulting fees or honoraria from AbbVie, Gilead, Janssen, Pharmacyclics, and Roche.
Barbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, has served as a consultant for AstraZeneca, Bristol-Myers Squibb, Janssen, Jazz Pharmaceuticals, Seattle Genetics, and Takeda/Millennium; and has served on speakers bureaus for Seattle Genetics, Takeda/Millennium, and Teva.
Nina Wagner-Johnston, MD, has nothing to disclose.
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER
John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc; Charles Willis, Director, Continuing Education, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
Lead Nurse Planner
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.
Planners
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
A. Kate MacDougall has nothing to disclose.
Patricia McLafferty has nothing to disclose.
Lynn Rubin has nothing to disclose.
Annie Yueh has nothing to disclose.
Content Reviewer
Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose.
Disclaimer
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.
Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
How to Earn Credit
To access the learning assessment and evaluation form online,
visit http://surveys.edmeasures.com/s3/PTP-CLL
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.